Repurposing benzimidazole and benzothiazole derivatives as potential inhibitors of SARS-CoV-2 : DFT, QSAR, molecular docking, molecular dynamics simulation, and in-silico pharmacokinetic and toxicity studies

Mohaptra, Ranjan K. and Dhama, Kuldeep and El-Arabey, Amr Ahmed and Sarangi, Ashish K. and Tiwari, Ruchi and Bin Emran, Talha and Azam, Mohammad and Raval, Mukesh K. and Seidel, Veronique and Abdalla, Mohnad (2021) Repurposing benzimidazole and benzothiazole derivatives as potential inhibitors of SARS-CoV-2 : DFT, QSAR, molecular docking, molecular dynamics simulation, and in-silico pharmacokinetic and toxicity studies. Journal of King Saud University - Science, 33 (8). 101637. (https://doi.org/10.1016/j.jksus.2021.101637)

[thumbnail of Mohapatra-etal-JKSUS-2021-Repurposing-benzimidazole-and-benzothiazole-derivatives-as-potential]
Preview
 Text. Filename: Mohapatra_etal_JKSUS_2021_Repurposing_benzimidazole_and_benzothiazole_derivatives_as_potential.pdf
Final Published Version
License: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 logo
Download (5MB)| Preview

Abstract

Density Functional Theory (DFT) and Quantitative Structure-Activity Relationship (QSAR) studies were performed on four benzimidazoles (compounds 1–4) and two benzothiazoles (compounds 5 and 6), previously synthesized by our group. The compounds were also investigated for their binding affinity and interactions with the SARS-CoV-2 Mpro (PDB ID: 6LU7) and the human angiotensin-converting enzyme 2 (ACE2) receptor (PDB ID: 6 M18) using a molecular docking approach. Compounds 1, 2, and 3 were found to bind with equal affinity to both targets. Compound 1 showed the highest predictive docking scores, and was further subjected to molecular dynamics (MD) simulation to explain protein stability, ligand properties, and protein–ligand interactions. All compounds were assessed for their structural, physico-chemical, pharmacokinetic, and toxicological properties. Our results suggest that the investigated compounds are potential new drug leads to target SARS-CoV-2.

ORCID iDs

Mohaptra, Ranjan K., Dhama, Kuldeep, El-Arabey, Amr Ahmed, Sarangi, Ashish K., Tiwari, Ruchi, Bin Emran, Talha, Azam, Mohammad, Raval, Mukesh K., Seidel, Veronique ORCID logoORCID: https://orcid.org/0000-0003-3880-5261 and Abdalla, Mohnad;
CORE (COnnecting REpositories)